Related Experiment Videos
Clinical aspects of GIP secretion
Acta Diabetologica Latina
|January 1, 1982
Summary
Gastric inhibitory polypeptide (GIP) secretion varies in several diseases, including diabetes and obesity. Impaired nutrient absorption and insulin feedback significantly impact GIP levels, affecting the entero-insular axis.
Area of Science:
- Endocrinology
- Gastroenterology
- Metabolic Research
Background:
- Gastric inhibitory polypeptide (GIP) is a key incretin hormone regulating the entero-insular axis.
- GIP release is stimulated by nutrient intake, particularly fats and glucose.
- GIP secretion patterns are altered in various metabolic and gastrointestinal conditions.
Purpose of the Study:
- To investigate the variations in GIP secretion across different diseases.
- To identify the primary factors influencing altered GIP secretion.
- To understand the role of GIP in the entero-insular axis in health and disease.
Main Methods:
- Observational study analyzing GIP secretion patterns.
- Comparison of GIP levels in patients with obesity, diabetes, and gastrointestinal disorders.
- Assessment of nutrient absorption and insulin feedback mechanisms.
Main Results:
- GIP secretion is increased in maturity onset diabetes mellitus, obesity, and duodenal ulcers.
- GIP levels are variable in chronic pancreatitis and cystic fibrosis, dependent on food intake and disease severity.
- GIP secretion is decreased in celiac disease and normal in insulinoma.
Conclusions:
- Altered GIP secretion is linked to impaired nutrient absorption and defective insulin feedback.
- GIP plays a crucial role in the entero-insular axis, with significant implications in metabolic diseases.
- Gastric acid secretion, emptying, and vagal control are secondary influences on GIP secretion.